Akero Therapeutics Inc’s recent filing unveils that its Director Graham G. Walmsley acquired Company’s shares for reported $9.6 million on Jan 30 ’25. In the deal valued at $48.00 per share,200,000 shares were bought. As a result of this transaction, Graham G. Walmsley now holds 1,000,000 shares worth roughly $51.15 million.
Then, Rolph Timothy sold 18,750 shares, generating $1,059,630 in total proceeds. Upon selling the shares at $56.51, the Chief Scientific Officer now owns 170,237 shares.
Before that, Young Jonathan sold 10,000 shares. Akero Therapeutics Inc shares valued at $538,061 were divested by the Chief Operating Officer at a price of $53.81 per share. As a result of the transaction, Young Jonathan now holds 251,147 shares, worth roughly $12.85 million.
BofA Securities upgraded its Akero Therapeutics Inc [AKRO] rating to a Buy from a a Neutral in a research note published on January 30, 2025; the price target was increased to $63 from $35. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late January has reiterated a ‘”a Buy”‘ rating for it. Citigroup began covering AKRO with “Buy” recommendation on November 18, 2024.
Price Performance Review of AKRO
On Monday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock fall -5.64% to $51.15. Over the last five days, the stock has lost -5.01%. Akero Therapeutics Inc shares have risen nearly 83.86% since the year began. Nevertheless, the stocks have risen 185.91% over the past one year. While a 52-week high of $58.40 was reached on 01/27/25, a 52-week low of $17.84 was recorded on 01/14/25. SMA at 50 days reached $33.83, while 200 days put it at $27.76.
Levels Of Support And Resistance For AKRO Stock
The 24-hour chart illustrates a support level at 49.54, which if violated will result in even more drops to 47.92. On the upside, there is a resistance level at 54.29. A further resistance level may holdings at 57.42. The Relative Strength Index (RSI) on the 14-day chart is 67.01, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 5.43, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 21.51%. Stochastics %K at 85.34% indicates the stock is a selling.
How much short interest is there in Akero Therapeutics Inc?
A steep rise in short interest was recorded in Akero Therapeutics Inc stocks on 2025-01-15, growing by 51522.0 shares to a total of 3.35 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 3.3 million shares. There was a rise of 1.54%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 19, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $69 price target.
